Allogeneic hematopoietic cell transplantation (HCT) is a curative option for patients with chemorefractory myeloid malignancies, 1 but 5-year overall survival (OS) and disease-free survival (DFS) rates have been limited to o20% owing to the high risks of relapse and transplant-related mortality (TRM).
1
but 5-year overall survival (OS) and disease-free survival (DFS) rates have been limited to o20% owing to the high risks of relapse and transplant-related mortality (TRM). 2 Conventional myeloablative regimens including cyclophosphamide (CY) combined with TBI or busulfan (BU) have been widely applied for patients with myeloid malignancies in remission, 3, 4 but optimal conditioning regimens have not been established for patients with malignancies not in remission before starting conditioning regimens.
The intensification of conditioning regimens has been attempted in order to offer stronger antitumor activity for highrisk diseases. [5] [6] [7] We previously reported that an intensified conditioning regimen with BU, melphalan (MEL) and TBI provided a 50% DFS rate at 3 years after HCT in patients with high-risk leukemia. 6 Another intensified regimen with BU, CY and TBI provided a 50% DFS rate at 5 years for patients with advanced myeloid malignancies including AML and CML. 7 Although intensified conditioning regimens did not improve short-term OS rates in previous studies because of increased TRM rates despite decreased relapse rates, [8] [9] [10] long-term follow-up outcomes have not been reported.
We retrospectively evaluated long-term outcomes of 44 consecutive patients who had allogeneic HCT from 1994 to 2003 for chemorefractory AML or CML in blast crisis (CML-BC) with intensified myeloablative conditioning regimens at our institution. Chemorefractory disease was defined as the presence of 45% blasts in bone marrow or the presence of extramedullary disease before starting conditioning regimens. Two types of regimens were used as follows: (1) BU 8 mg/kg (orally 1 mg/kg every 6 h from day − 8 to − 6) + CY 120 mg/kg (IV 60 mg/kg on days − 5 and − 4)+TBI 10 Gy (in 4 fractions on days − 2 and − 1; n = 20); and (2) BU 8 mg/kg (orally 1 mg/kg every 6 h from days − 6 to − 4) + MEL 180 mg/m 2 (IV 60 mg/m 2 from days − 9 to − 7) + TBI 10 Gy (in 4 fractions on days − 2 and − 1; n = 24). 6 Regimens were selected according to physician discretion. GVHD prophylaxis consisted of tacrolimus or cyclosporine combined with short-term methotrexate. One exceptional patient had GVHD prophylaxis with cyclosporine and antithymocyte globulin.
Serological HLA matching of recipients and donors was performed on at least A, B and DR loci. Neutrophil and platelet engraftments were defined as the achievement of an absolute neutrophil count ⩾ 500/μL for three consecutive days and a platelet count ⩾ 50,000/μL without transfusion support for seven consecutive days. Regimen-related toxicity was graded using the National Cancer Institute Common Toxicity Criteria version 4.0. Statistical analyses were performed by Stata version 12 (Stata Corp., College Station, TX, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan).
Patient characteristics are summarized in Table 1 . Thirty out of 44 (68%) patients had circulating blasts in their peripheral blood before starting conditioning regimens. The median percentage of blasts was 39% in the bone marrow (range, 0-100%) and 2 patients with CML-BC had extramedullary disease without blasts in the bone marrow. No significant differences were observed in patient characteristics between the regimens, except for younger patient age in the BU+MEL+TBI regimen. Abbreviations: ATG = antithymocyte globulin; BM = bone marrow; BU = busulfan; CB = cord blood; CML-BC = CML in blast crisis; CY = cyclophosphamide; MDS = myelodysplastic syndrome; MEL = melphalan; MTX = methotrexate; PB = peripheral blood stem cell; PIF = primary induction failure.
Regimen-related organ toxicities were graded in 42 patients with medical records. Grades 3-5 non-hematological organ toxicities developed in 40 patients (95%). The most frequent grades 3-5 toxicities were mucositis (50% and 79%) and febrile neutropenia (89% and 96%) with BU+CY+TBI and BU+MEL+TBI regimens, respectively. Most patients responded to antibiotic therapy and became afebrile, typically after neutrophil recovery. Thrombotic microangiopathy (TMA) developed in four patients (9%).
Neutrophil engraftment was achieved in 40 patients (93%), at a median of 14 days (range 11-31 days). Platelet engraftment was achieved in 33 patients (75%), at a median of 32 days (range 18-328 days). No significant difference was observed in the incidence of neutrophil or platelet engraftment between conditioning regimens.
The cumulative incidence rates of grades II-IV and III-IV acute GVHD were 55% (95% confidence interval (CI), 37-70%) and 36% (95% CI, 18-54%), respectively, at 100 days after HCT. The cumulative incidence rate of extensive chronic GVHD was 48% (95% CI, 26-67%) at 2 years after HCT. No significant difference was noted between conditioning regimens.
The median follow-up period among survivors was 11.2 years (range 3.6-18.8 years). The 10-year OS and DFS rates were 34% (95% CI, 20-48%) and 29% (95% CI, 16-43%), respectively ( Figure 1a ). Patients conditioned with BU+MEL+TBI had a slightly higher OS rate (45 versus 20% at 10 years; P = 0.06) and a significantly higher DFS rate than those conditioned with BU+CY +TBI (41 versus 14% at 10 years; P = 0.03; Figure 1b) . Multivariate Cox analysis revealed that the percentage (⩾5%) of blasts in the peripheral blood before starting conditioning and the BU+CY+TBI regimen compared with the BU+MEL+TBI regimen were associated with risks of overall mortality (hazard ratio (HR) 3.28, 95% CI 1.51-7.15, P = 0.003; and HR 2.73, 95% CI 1.26-5.92, P = 0.01, respectively), and mortality or relapse (HR 3.53, 95% CI 1.61-7.73, P = 0.002; and HR 2.74, 95% CI 1.27-5.92, P = 0.01, respectively). The cumulative incidence rate of TRM was 40% (95% CI, 25-55%) at 10 years (Figure 1c) , and did not differ significantly between conditioning regimens (34% with BU+ MEL+TBI and 48% with BU +CY+TBI; P = 0.28; Figure 1d ). The cumulative incidence of relapse was 31% (95% CI, 18-46%) at 10 years (Figure 1e) , and did not differ significantly between conditioning regimens (25% with BU+ MEL+TBI and 39% with BU+CY+TBI; P = 0.32; Figure 1f ). Twenty-nine patients (66%) had died at the last follow-up. Relapse was the most frequent cause of death (n = 10; 35%), followed by infection (n = 6; 21%), TMA (n = 2; 7%), acute GVHD (n = 2; 7%), non-infectious lung complications (n = 2; 7%), cerebral hemorrhage (n = 2; 7%), heart failure (n = 1; 3%), secondary rectal cancer (n = 1; 3%), ileus (n = 1; 3%), non-specific colitis (n = 1; 3%) and liver cirrhosis (n = 1; 3%). The causes of death did not differ significantly between conditioning regimens.
Late complications were evaluated at the last follow-up among the 11 disease-free survivors of 45 years. The most frequent late complications included hyperlipidemia (n = 8; 73%), renal dysfunction (n = 5; 45%), iron overload (n = 2; 18%) and osteonecrosis (n = 2; 18%). Secondary malignancy (rectal cancer) developed in one patient (9%). Renal dysfunction was slightly more frequent after BU+CY+TBI than after BU+MEL+TBI (75% and 29%, respectively; P = 0.24).
The Center for International Blood and Marrow Transplant Research previously reported a 3-year OS rate of 19% among 1673 chemorefractory AML patients undergoing allogeneic HCT with TBI or BU-based myeloablative conditioning regimens.
11 A retrospective study using the Japanese transplantation registry database showed a 3-year OS rate of 15-25% among patients with AML not in remission who underwent HCT mostly with the BU+CY or CY+TBI regimen. 12 A study by the European Society for Blood and Marrow Transplantation reported a 2-year OS rate of 16% after allogeneic HCT for patients with CML-BC. 13 In the present study, even though circulating blasts were present in 68% of patients, our intensified myeloablative conditioning regimens provided a 10-year OS rate of 34%. Notably, the 10-year OS and DFS rates exceeded 40% with the BU+MEL+TBI regimen.
An increase in the frequency of regimen-related toxicities has been a barrier after intensified conditioning regimens. 8 We observed a high frequency of severe mucositis and febrile episodes before engraftment in the present study, but they were transient and managed by supportive treatment.
Previous studies from the Seattle group compared CY+TBI with BU+CY+TBI and reported that 3-year DFS rates were similar, and BU+CY+TBI was associated with a slightly lower relapse rate (28 versus 54%) and higher TRM rate (68 versus 36%). 9 The median patient age in the BU+CY+TBI group in that study was older than that in ours (41 versus 32 years old). This difference may account for the lower incidence of TRM in our study. In a previous study, the relapse rate was lower in patients conditioned with MEL+TBI than in those conditioned with CY+TBI, but this benefit was offset by the increased rate of TRM. 10 In the present study, patients conditioned with BU+MEL+TBI had a slightly lower relapse rate and TRM than those conditioned with BU+CY+TBI.
Hyperlipidemia was the most frequent late complication among the long-term survivors, which is consistent with recent findings.
14 Renal dysfunction was observed in 45% of long-term survivors and the incidence appeared to be higher in patients conditioned with CY than with MEL, which is consistent with previous findings.
15
This study has several limitations. The results need to be compared with the most frequently used standard myeloablative regimens such as BU+CY or CY+TBI. Furthermore, this was a retrospective study including a limited number of patients at a single institution. Therefore, a prospective randomized study is warranted in order to confirm our results. Nevertheless, the DFS rates obtained in the present study are encouraging given the poor prognosis of patients with chemorefractory myeloid malignancies, and our results suggest that intensified myeloablative conditioning regimens may improve long-term DFS for these patients.
